Spectrumedics Medical

Spectrumedics Medical is a Singapore-based medical device company building active, minimally-invasive cardiovascular interventional systems. Its flagship product, the Sonico-CX intravascular lithotripsy (IVL) system, uses acoustic pressure waves to break up calcified coronary lesions so cardiologists can restore blood flow and place stents. In January 2026 the company earned an EU CE mark, joining Johnson & Johnson MedTech's Shockwave and Elixir Medical as one of the few companies with EU-approved coronary IVL systems. Backed by a Series A round led by Legend Capital, Spectrumedics operates from the JTC MedTech Hub and is commercializing across Asia Pacific and Latin America while expanding into Europe and the Middle East.